BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $172,798,000 | -0.6% | 2,228,501 | +10.1% | 0.09% | +2.2% |
Q4 2021 | $173,819,000 | +13.1% | 2,024,918 | +5.9% | 0.09% | +2.3% |
Q3 2021 | $153,729,000 | +0.9% | 1,911,340 | +1.0% | 0.09% | +2.4% |
Q2 2021 | $152,320,000 | -0.8% | 1,892,171 | +4.0% | 0.08% | -3.4% |
Q1 2021 | $153,485,000 | +8.5% | 1,819,841 | +3.2% | 0.09% | 0.0% |
Q4 2020 | $141,450,000 | -5.9% | 1,762,841 | -5.7% | 0.09% | -18.5% |
Q3 2020 | $150,365,000 | -9.2% | 1,869,750 | -2.8% | 0.11% | -15.0% |
Q2 2020 | $165,612,000 | +8.4% | 1,923,485 | +2.2% | 0.13% | -9.3% |
Q1 2020 | $152,771,000 | +3.0% | 1,881,642 | +6.1% | 0.14% | +29.6% |
Q4 2019 | $148,311,000 | -7.6% | 1,773,632 | -3.3% | 0.11% | -16.3% |
Q3 2019 | $160,481,000 | +8.9% | 1,834,699 | +2.0% | 0.13% | +5.7% |
Q2 2019 | $147,300,000 | +0.6% | 1,798,533 | -0.1% | 0.12% | -3.2% |
Q1 2019 | $146,391,000 | +27.1% | 1,800,411 | +2.9% | 0.13% | +10.5% |
Q4 2018 | $115,194,000 | -14.1% | 1,750,136 | +0.6% | 0.11% | -2.6% |
Q3 2018 | $134,159,000 | +5.7% | 1,740,294 | +1.2% | 0.12% | -2.5% |
Q2 2018 | $126,937,000 | +14.7% | 1,719,082 | +1.0% | 0.12% | +10.1% |
Q1 2018 | $110,671,000 | +3.9% | 1,701,580 | +3.3% | 0.11% | +2.8% |
Q4 2017 | $106,521,000 | +1.8% | 1,647,914 | -1.1% | 0.11% | -7.0% |
Q3 2017 | $104,588,000 | +8.4% | 1,666,746 | +4.6% | 0.11% | -0.9% |
Q2 2017 | $96,439,000 | +94.8% | 1,592,975 | +66.9% | 0.12% | +51.3% |
Q1 2017 | $49,496,000 | -24.3% | 954,417 | -35.3% | 0.08% | -16.5% |
Q4 2016 | $65,421,000 | -18.4% | 1,475,440 | -12.4% | 0.09% | -24.2% |
Q3 2016 | $80,191,000 | +1.3% | 1,684,679 | -3.7% | 0.12% | -4.0% |
Q2 2016 | $79,144,000 | +17.5% | 1,750,195 | +6.7% | 0.12% | +14.7% |
Q1 2016 | $67,374,000 | +19.8% | 1,640,064 | +11.3% | 0.11% | +13.5% |
Q4 2015 | $56,239,000 | +33.3% | 1,474,153 | +14.8% | 0.10% | +17.1% |
Q3 2015 | $42,196,000 | -35.1% | 1,284,519 | +38.1% | 0.08% | -35.4% |
Q2 2015 | $65,059,000 | +2.2% | 930,345 | +0.1% | 0.13% | -0.8% |
Q1 2015 | $63,636,000 | -6.0% | 928,989 | +0.6% | 0.13% | -10.5% |
Q4 2014 | $67,712,000 | +0.1% | 923,890 | -2.0% | 0.14% | -4.7% |
Q3 2014 | $67,638,000 | +0.2% | 942,428 | +1.0% | 0.15% | -1.3% |
Q2 2014 | $67,487,000 | +1.6% | 933,436 | +3.4% | 0.15% | -3.8% |
Q1 2014 | $66,431,000 | +5.8% | 902,836 | +0.1% | 0.16% | +3.9% |
Q4 2013 | $62,761,000 | +9.2% | 902,380 | +3.1% | 0.15% | -2.6% |
Q3 2013 | $57,490,000 | -1.7% | 875,169 | +3.7% | 0.16% | -8.2% |
Q2 2013 | $58,472,000 | – | 844,118 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |